Last reviewed · How we verify
Camrelizumab plus chemo-radiotherapy
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses, combined with chemotherapy and radiotherapy for synergistic cancer cell killing.
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses, combined with chemotherapy and radiotherapy for synergistic cancer cell killing. Used for Locally advanced or metastatic nasopharyngeal carcinoma (in combination with chemotherapy and/or radiotherapy), Other solid tumors in combination with chemo-radiotherapy (Phase 3 investigation).
At a glance
| Generic name | Camrelizumab plus chemo-radiotherapy |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and restoring anti-tumor immunity. When combined with chemotherapy and radiotherapy, the regimen leverages immunogenic cell death from chemo-radiation to amplify the checkpoint inhibition effect, creating a multi-modal attack on cancer cells.
Approved indications
- Locally advanced or metastatic nasopharyngeal carcinoma (in combination with chemotherapy and/or radiotherapy)
- Other solid tumors in combination with chemo-radiotherapy (Phase 3 investigation)
Common side effects
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Fatigue
- Nausea and vomiting
- Hematologic toxicity (anemia, leukopenia, thrombocytopenia)
Key clinical trials
- Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) (PHASE3)
- Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE3)
- Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer (PHASE2)
- PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC (PHASE2)
- DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI (PHASE2)
- A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial (PHASE2, PHASE3)
- PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC (PHASE3)
- Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camrelizumab plus chemo-radiotherapy CI brief — competitive landscape report
- Camrelizumab plus chemo-radiotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI